Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa

Journal of the National Cancer Institute

Volumn 94, Issue 10, 2002, Pages 718-732

  Otieno, Mwanda W ^a   Banura, Cecily ^b   Katongole Mbidde, Edward ^b   Johnson, John L ^c,d   Ghannoum, Mahmoud ^d   Dowlati, Afshin ^d,e   Renne, Rolf ^d,e   Arts, Eric ^c,d   Whalen, Christopher ^c,d   Lederman, Michael M ^c,d   Remick, Scot C ^d,e  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDINAVIR; ISONIAZID; LAMIVUDINE; LOMUSTINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RIFAMPICIN; STAVUDINE; VINCRISTINE; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL FEATURE; CONTROLLED STUDY; EPIDEMIC; EPSTEIN BARR VIRUS; FEMALE; HEALTH CARE COST; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MALE; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TUBERCULOSIS; UNITED STATES; VIRUS LOAD;

EID: 0037094183     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.10.718     Document Type: Review

References (203)

1. Obstacles to the optimal management of HIV infection/AIDS in Africa
2. AIDS in Africa: An epidemiologic paradigm
3. The AIDS epidemic - Considerations for the 21st century
4. Removing obstacles to healthy development
5. AIDS crushes a continent
6. Africa's plague
7. How we can fight the disease
8. Orphans, the lasting victims
9. AIDS - Remarkable progress. But fewer than 10 percent of the world's AIDS patients have access to new therapies
10. Death stalks a continent
11. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
12. The spectrum of non-AIDS-defining neoplastic disease in HIV infection
13. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome
14. Pneumocystis pneumonia - Los Angeles
15. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California
16. Diffuse undifferentiated non-Hodgkins lymphoma among homosexual males - United States
17. Primary lymphoma of the nervous system associated with acquired immune-deficiency syndrome
18. Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States
19. AIDS epidemic cuts cancer survival in younger men
20. Acquired Immunodeficiency Syndrome-related Non-Hodgkin's Lymphoma
21. Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine
22. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy
23. Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma
24. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy
25. Posttransplant malignancies
26. Post-transplant lymphoproliferative disorders: Implications for acquired immunodeficiency syndrome-associated malignancies
27. The epidemiology of acquired immunodeficiency syndrome malignancies
28. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center
29. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
30. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. Swiss HIV Cohort Study
31. AIDS across Europe, 1994-98: The EuroSIDA study
32. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
33. The double burden of HIV infection and tuberculosis in sub-Saharan Africa
34. Slim disease: A new disease in Uganda and its association with HTLV-III infection
35. Cancer in Kampala, Uganda, in 1989-91: Changes in incidence in the era of AIDS
36. Cancer in the African population of Harare, Zimbabwe, 1990-1992
37. AIDS-related cancers in Africa: Maturation of the epidemic in Uganda
38. Kaposi's sarcoma in South Africa
39. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997
40. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic
41. Kaposi's sarcoma in childhood: An analysis of 100 cases from Uganda and relationship to HIV infection
42. Cancer and HIV infection in Rwanda
43. Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa
44. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms
45. Non-Hodgkin lymphoma in Uganda: A case-control study
46. The spectrum of HIV-1 related cancers in South Africa
47. AIDS and cancer in Africa: The evolving epidemic in Zimbabwe
48. Effect of HIV infection on the incidence of lymphoma in Africa
49. The malignant lymphomas of Kenya: Morphology, immunophenotype, and frequency of Epstein-Barr virus in 73 cases
50. HIV-associated malignant lymphomas in Kenya (Equatorial Africa)
51. Adult Burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya
52. Primary cerebral lymphoma in Zimbabwe: A report of three patients
53. Neuropathology of human immunodeficiency virus 1 infection. Significance of studying in forensic autopsy cases at Dar es Salaam, Tanzania
54. Molecular pathogenesis of AIDS-related non-Hodgkin's lymphoma
55. Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis
56. AIDS-related malignancies: The emerging epidemic
57. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy
58. Molecular pathogenesis of HIV-associated lymphomas
59. Pathogenesis of AIDS lymphomas
60. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line
61. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: Association with diffuse large-cell subtype
62. Role of human immunodeficiency virus type 1 and other viruses in malignancies associated with acquired immunodeficiency disease syndrome
63. Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas
64. HIV insertional cis-activation of the proto-oncogene c-fes in AIDS associated lymphomagenesis
65. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice
66. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
67. Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 tat-expressing transgenic mice
68. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study
69. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease
70. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
71. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection
72. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas
73. Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus
74. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease
75. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
76. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells
77. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences
78. HHV-8 is present in multiple myeloma patients
79. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
80. Kaposi's sarcoma-associated herpesvirus and multiple myeloma: Lack of criteria for causality
81. Bone marrow failure associated with human herpesvirus 8 infection after transplantation
82. + hematopoietic stem cells are susceptible to KSHV infection in vitro
83. Epstein-Barr virus and its replication
84. Current perspectives on the molecular pathogenesis of virus-induced cancers in human immunodeficiency virus infection and acquired immunodeficiency syndrome
85. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients
86. Epstein-Barr virus infection
87. Detection of Epstein-Barr virus genomes in AIDS related lymphomas: Sensitivity and specificity of in situ hybridisation compared with Southern blotting
88. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma
89. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients
90. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture
91. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus
92. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen
93. p53 inhibition by the LANA protein of KSHV protects against cell death
94. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma
95. The role of human immunodeficiency virus-I in the pathogenesis of acquired immunodeficiency syndrome-related Kaposi's sarcoma: The importance of an inflammatory and angiogenic milieu
96. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus-8: Determinants of its pathogenicity?
97. Nucleotide sequence of the Kaposi's sarcoma-associated herpesvirus (HHV-8)
98. Human herpesvirus 8 k1-associated nuclear factor-kappa b-dependent promoter activity: Role in Kaposi's sarcoma inflammation?
99. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus
100. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene
101. Kaposi's sarcoma-associated herpesvirus: A new DNA tumor virus
102. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B
103. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University Medical Center experience with 105 patients (1981-1986)
104. Acquired immunodeficiency syndrome-related lymphoma
105. Acquired immunodeficiency syndrome-related lymphomas: Clinical aspects
106. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
107. AIDS-related malignant lymphoma: Results of prospective treatment trials
108. AIDS-associated non-Hodgkin's lymphoma in San Francisco
109. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial
110. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial
111. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by (AZT) and other dideoxynucleoside congeners of thymidine
112. Acquired immunodeficiency syndrome-associated lymphomas
113. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials plus granulocyte-macrophage colony-stimulating factor
114. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen
115. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
116. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type 1-related non-Hodgkin's lymphoma: A highly active regimen
117. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in HIV-associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group trial (E1494)
118. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in HIV-associated non-Hodgkin's lymphoma (NHL): An Eastern Cooperative Oncology Group trial (E1494)
119. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma
120. Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies
121. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: Evaluation of the role of G-CSF; Quality-of-life analysis and long-term follow-up
122. Risk of infectious complications in patients taking glucocorticosteroids
123. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS)
124. Steroid-related development of Kaposi's sarcoma in a homosexual man with Burkitt's lymphoma
125. Steroid-induced Kaposi's sarcoma in a patient with pre-AIDS
126. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy
127. Dose-adjusted EPOCH chemotherapy (CT) in previously untreated HIV-associated non-Hodgkin's lymphoma (HIV-NHL): Preliminary report of efficacy, immune reconstitution, and HIV control following therapy
128. Dose-adjusted EPOCH chemotherapy (CT) with suspension of antiretroviral therapy (ART) for HIV-associated non-Hodgkin's lymphoma (HIV-NHL)
129. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma: A review of the Einstein, Aviano, and ECOG experience in 182 patients
130. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter phase II trial
131. Hematologic disorders and growth factor support in HIV infection
132. Lack of in vitro effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1
133. Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony stimulating factor
134. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial
135. A pilot study in the use of GM-CSF in human immunodeficiency virus (HIV) infected individuals
136. HIV viral burden (VB) during EPOCH chemotherapy (CT) for HIV-related lymphomas
137. Effects of standard chemotherapy regimens on HIV plasma RNA levels in patients with HIV-associated malignancies
138. Pathophysiology and management of HIV-associated hematologic disorders
139. Antiretroviral therapy and immunomodulators in patients with AIDS
140. Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors
141. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
142. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor
143. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir
144. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy
145. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
146. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: Biologic correlates of clinical outcome
147. Activation of HHV-8 by HIV-1 tat
148. Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy
149. Impact of highly active antiretroviral therapy (HAART) on HIV-associated primary central nervous system lymphoma (PCNSL)
150. Survival of AIDS patients with primary central nervous system lymphoma (PCNSL) is dramatically improved by HAART-induced recovery
151. Azothymidine and interferon-alpha are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma
152. Complete remission of a primary effusion lymphoma with antiretroviral therapy
153. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy
154. Apparent spontaneous regression of primary CNS lymphoma mimicking resolving toxoplasmosis
155. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy
156. Surveillance for AIDS in Uganda
157. Human immunodeficiency virus and AIDS in Uganda
158. HIV-associated tuberculosis in developing countries: Epidemiology and strategies for prevention
159. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
160. Efficacy of trimethoprim-sulfamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: A randomized controlled trial
161. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: An evaluation of the provisional WHO/UNAIDS recommendations
162. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
163. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma
164. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome: A retrospective analysis and review of the literature
165. Primary central nervous system lymphoma
166. Primary central nervous system lymphoma in acquired immune deficiency syndrome: A clinical and pathological study
167. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system
168. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma
169. Primary central nervous system lymphoma in patients with AIDS
170. Primary central nervous system lymphomas in patients with acquired immunodeficiency syndrome (AIDS)
171. Rapid differential diagnosis of cerebral toxoplasmosis and primary central nervous system lymphoma by thallium-201 SPECT
172. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma
173. Primary central nervous system lymphoma: Natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome
174. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2
175. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
176. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
177. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lympho-proliferative disorders: Evaluation of response on 48 patients
178. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
179. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
180. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade non-Hodgkin's lymphoma (NHL)
181. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
182. Rituximab therapy of lymphoproliferative disorders in immunosuppressed patients
183. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorders: A retrospective analysis of 32 patients
184. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
185. Survival benefit from high-dose chemotherapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma
186. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
187. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes des l'Adultes Study
188. Hematopoietic stem cells in HIV disease
189. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
190. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
191. Immunotherapy for Epstein-Barr virus-associated cancers
192. A phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies
193. Phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies
194. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
195. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
196. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
197. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins
198. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo
199. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents
200. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
201. Acquired immunodeficiency syndrome-associated cancers in sub-Saharan Africa